The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer
Official Title: Registry to Evaluate Effectiveness and Safety of the NanoKnife System for the Ablation of Stage 3 Pancreatic Adenocarcinoma
Study ID: NCT03899649
Brief Summary: This multicenter, observational study will evaluate the effectiveness and safety of the NanoKnife System when used for the ablation of Stage 3 pancreatic adenocarcinoma (Stage 3 PC). Eligible patients will be recruited over a 36-month period and participating institutions will enroll and provide data on consecutive patients that meet inclusion and exclusion criteria. Each patient will be followed up for the duration of the study or until death. The study will include two (2) cohorts: patients who received standard of care (SOC) and received irreversible electroporation (IRE) \[IRE cohort\], and patients who were treated with SOC and did not receive IRE \[SOC cohort\].
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Moores Cancer Center, UC San Diego Health, La Jolla, California, United States
University of Florida Health, Gainesville, Florida, United States
Miami Cancer Institute, Miami, Florida, United States
Wellstar Medical Group, Marietta, Georgia, United States
Northwest Community Hospital, Arlington Heights, Illinois, United States
University of Iowa Healthcare, Iowa City, Iowa, United States
Norton Healthcare, Louisville, Kentucky, United States
Mayo Clinic, Rochester, Rochester, Minnesota, United States
Barnes-Jewish Hospital, Saint Louis, Missouri, United States
NYU Langone, New York, New York, United States
Presbyterian Hospital, Columbia, New York, New York, United States
Atrium Health, Charlotte, North Carolina, United States
St. Luke's University Health Network, Easton, Pennsylvania, United States
University of Texas-Southwestern, Dallas, Texas, United States